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Abstract
Background: Mevalonate kinase deficiency is a metabolic autoinflammatory syndrome caused by mutations in the
MVK gene, mevalonate kinase, the key enzyme in the non-sterol isoprenoid biosynthesis pathway. Two phenotypes
of mevalonate kinase deficiency are known based on the level of enzymatic deficiency, mevalonic aciduria and
hyperimmunoglobulinemia D syndrome, but a wide spectrum of intermediate phenotypes has been reported.
Currently one of the most effective treatments is biological therapy (with interleukin-1 antagonist anakinra or
tumour necrosis factor-α inhibitor etanercept).
Case presentation: The patient in this case has a phenotype contributing to a severe disease that caused the
symptoms to manifest very early, in the prenatal period. Mevalonate kinase deficiency was suspected on the basis
of clinical (hydrops fetalis, hepatosplenomegaly, hypotonia) and laboratory signs (anaemia, intense acute phase
reaction, increased urinary excretion of mevalonic acid). Mutation analysis of the MVK gene confirmed the biochemical
diagnosis. Treatment with the interleukin-1 antagonist anakinra was started (minimal dose of 1 mg/kg/day)
and revealed its efficacy after three days.
Conclusions: Our case highlights the need for a very detailed clinical and laboratory assessment in new-borns with
any suggestion of autoinflammatory disorders. It is important that patients are diagnosed as early as possible
to provide better multidisciplinary follow-up and therapy when needed.
Keywords: Mevalonate kinase deficiency, Mevalonic aciduria, Hyperimmunoglobulinemia D syndrome,
Autoinflammatory syndrome, IL-1 antagonist
Background
Mevalonate kinase deficiency (MKD) is a rare inborn
error of metabolism caused by deficiency in the enzyme
mevalonate kinase [1, 2]. It disrupts synthesis of
cholesterol and non-sterol isoprenoids [1–7]. There
are two forms of mevalonate kinase deficiency: mevalonic
aciduria (MA), when residual function of the enzyme is
undetectable (<1 % [3] or <0.5 % [8] according to different
authors) and hyperimmunoglobulinemia D syndrome
(HIDS), when residual function of the enzyme is 1.8–28 %
[3, 9] (or 1–10 % [8]). Literature reveals about 30 cases of
MA, while the milder form, HIDS, is ten times more
common [2, 5, 10]. There is evidence that phenotypes of
MA and HIDS overlap; patients with the HIDS phenotype
develop neurologic symptoms later in life [11–13].
The pathogenesis of the disease is not definitely de-
fined. Currently persistent systemic inflammation is
thought to be the main pathogenic factor of the disease.
The inflammation originates from impaired synthesis of
non-sterol isoprenoids, namely farnesylpyrophosphate
and geranylgeranylpyrophosphate that are used for pro-
tein prenylation [1, 3, 13]. The lack of prenylation leads
to changed localization and functional activity of some
proteins, e.g. overactivity of small GTPases. As a result
inflammasome complexes are formed that activate
caspase-1 and hypersecretion of IL-1β is mediated.
There is data that inflammasome can also be activated
by reactive oxygen species and mitochondrial dysfunction
[3]. In mevalonic aciduria it is assumed that disruption in
cholesterol synthesis mostly influences brain development
[1, 10]. Exogenous cholesterol obtained with food meets
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the needs of steroid hormones, biliary acid synthesis,
etc. but does not pass the blood–brain barrier. There-
fore, neuronal myelinisation and the stability of the
brain cell membrane is disturbed, and neurologic
symptoms develop.
Although the clinical expression of mevalonate kinase
deficiency can vary, the disease generally starts in in-
fancy [2, 3, 5, 7, 10]. For the milder form (HIDS), the
most specific symptom is recurrent episodes of fever
with or without lymphadenopathy, arthralgia, myalgia,
abdominal pain, diarrhoea, vomiting, polymorphic skin
rash, and mucosal ulcers [2, 3, 5, 7–11, 14]. In some
severe cases of mevalonic aciduria, hydrops fetalis and
intrauterine growth restriction are observed. MA
phenotype include hepatosplenomegaly, cholestatic
jaundice, diarrhoea, vomiting, mild dysmorphic features
(dolichocephaly, microcephaly, triangular-shaped face,
down-slanting eyelids, dysplastic ears), and failure to
thrive [2, 3, 5, 9–11, 14]. Hypotonia is observed from
birth and cerebellar ataxia progresses during the
course of the disease; psychomotor development may
differ [2, 3, 5, 7, 10, 11]. Ocular impairment, such as
cataract, uveitis, retinitis, can be identified in the
course of the disease [2, 3, 5, 10, 11]. A wide spectrum of
intermediate phenotypes has been reported [13].
Laboratory tests show intense acute phase reaction,
anaemia, direct hyperbilirubinemia, and increased
urinary excretion of mevalonic acid which can persist
in MA patients and occurs during febrile attack in
HIDS patients [3, 5, 7, 8, 10, 11]. Two-thirds of patients
have elevated serum IgA and IgD [3, 10]. Diagnosis is
confirmed by the genetic mutation being identified
for patient and parents [3, 5, 10]. Prenatal diagnosis
is possible (if there were cases in the family). After an am-
niocentesis or chorionic villous biopsy is performed, the
activity of mevalonate kinase or the presence of mutations
in the mevalonate kinase (MVK) gene can be determined
[2, 5, 10]. Preimplantation genetic diagnosis should be
discussed in families affected by a particularly severe
form of MKD. Prenatal diagnosis and preimplantation
genetic diagnosis should be performed after genetic
counselling [15].
The aim of this case report is to describe the patient’s
medical history between the first prenatal symptoms and
the diagnosis of MKD and report the efficacy of timely
treatment with the IL-1 antagonist anakinra.
Case presentation
The patient is a male infant born to healthy non-
consanguineous Lithuanian parents. The mother’s age at
delivery was 32 years old, and this was her first preg-
nancy. From the 31st week of pregnancy, she started to
complain about pain in her left flank. Acute pyeloneph-
ritis was suspected and antibiotics were prescribed, but
the urine culture was negative. The foetal ultrasound in
the 31st week was normal. Since the pain deteriorated,
on the 33rd week ultrasound was repeated and revealed
foetal ascites, hydrocele, hepatosplenomegaly, moderate
anaemia, tricuspid regurgitation, and polyhydramnios.
Because of the critical foetal condition, an urgent C-
section was performed. The male infant weighed 2 676 g
and had a height of 48 cm and occipital-frontal circum-
ference of 33.5 cm. The Apgar score was 8–8. Immedi-
ately after birth, hepatosplenomegaly, ascites and
hydrothorax were observed. In the first week of life, a
diffuse maculopapular rash appeared. Laboratory data
showed severe anaemia, intense acute phase reaction,
direct hyperbilirubinemia, elevated liver enzymes, meta-
bolic acidosis, and hypokalaemia. TORCH titters, as well
as blood and spinal fluid cultures, were negative. From
the first hours of life, the new-born was treated with red
blood cell transfusions, empiric antibiotics, sodium bi-
carbonate, and ursodeoxycholic acid. There was no
therapeutic response to empiric antibiotics. On the 7th
day of life, feeding problems, lethargy, and hypotonia
were observed. At the end of the 2nd week, bloody diar-
rhoea, failure to thrive, and short (1–2-day) recurrent fe-
brile episodes started. Screening for metabolic disorders
performed on the 16th day revealed increased urinary ex-
cretion of mevalonic acid, which is characteristic of
mevalonate kinase deficiency. Given a presumed diagno-
sis of MKD, on the 9th week of life he began to be
treated with the IL-1 antagonist anakinra (1 mg/kg/day)
on a daily basis. After a few days of treatment, the boy
became more active, his temperature remained normal,
his diarrhoea ceased, pronounced weight gain was ob-
served (at first the patient gained 200 g in 2 months and
after anakinra he gained 600 g in 3 weeks), and systemic
inflammatory reaction markers and haemoglobin returned
to normal (Fig. 1). Mutation analysis of the MVK gene re-
vealed that the boy was homozygote for the nucleotide
substitution c.1162C > T, leading to the aminoacid R388
change to a stop codon (p.R388Ter). The nonsense muta-
tion has already been reported in the Infevers database at
http://fmf.igh.cnrs.fr/ISSAID/infevers/ and also identified
in other patients of Eastern Europe origin [16]. On follow-
up at the chronological age of 4 months (adjusted age of
2 months), the boy was thriving but the weight was on the
3rd percentile, he had no febrile attacks, and according to
the mother every month he had intermittent periods of
abdominal pain and diarrhoea that lasted for a week.
The patient made eye contact, smiled back, and bab-
bled but his head control was insufficient. On the examin-
ation at the chronological age of 7 months monthly
periods of diarrhoea persisted, failure to thrive was ob-
served – weight was less than 3rd percentile. There were
no febrile attacks. Motor development was impaired: the
patient didn’t sit, head control was insufficient and
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hypotonia remained though mental development was nor-
mal. At the age of one year the patient had severe febrile
attack with bloody diarrhoea after routine immunization,
weight gain was extremely low. He developed normal head
control, crawled, sitted with self support, played with toys.
The dosage of anakinra was increased to 2 mg/kg/day and
prednisone (2 mg/kg/day) was added to treatment. After
3 months of this treatment the patient was thriving better,
periods of diarrhoea were less severe. Brain MRI,
performed at age 1 years and 4 months, showed no
structural abnormalities. Patient’s motor development
have improved after intense rehabilitation, however it
is still significantly delayed: he stands up and walks
with considerable support, hypotonia remains (more
pronounced in legs). The boy shows interest in the
surroundings, communicates willingly, speaks with
solitary words, builds a tower of blocks.
Conclusions
The patient’s disease in this case report presented in the
perinatal period, and due to its progression an emer-
gency C-section was performed. Such early manifest-
ation of the disease usually leads to a severe course and
poorer outcome. Molecular genetic testing shown the
previously reported homozygous mutation c.1162C > T
of the MVK gene. Until 2012, 103 different mutations
within the MVK had been described [3]. MKD is inherited
in an autosomal recessive manner. A majority of the
patients have compound heterozygous mutations but
homozygous mutations have also been detected [3, 5, 10].
It has been noted that with a homozygous mutations
the course of the disease is more severe and progno-
sis is poorer [3]. The phenotype of our patient was
caused by a homozygous mutation in MVK gene and
manifested in perinatal period. Thus, after evaluation
of disease progression we conclude that the pheno-
type is of intermediate severity.
The diagnosis was made in a timely manner compared
with data in the literature (sometimes it takes years to
decades [11, 14]). It is important because the undiag-
nosed disease impact quality of life of the patient and
parents also aggravate the work of the health care sys-
tem (multiple hospitalisations, unnecessary exams and
treatments) [14]. However secondary impairment of un-
controlled inflammation, such as amyloidosis, in MKD is
rare [3, 14, 17]. There was a multicenter study including
18 countries performed and amyloidosis was found in
2,9 % of HIDS patients [17].
We could hypothesize that symptoms of the mother‘s
pyelonephritis were caused by mevalonic acid excretion
since there are cases described [5]. However there is no
data in the past literature about treating the pregnant
woman. The patient was treated with systemic cortico-
steroids (methylprednisolone) and later with anakinra as
soon as the diagnosis of mevalonate kinase deficiency
was suspected. According to the past literature, recur-
rent episodes of fever were treated with non-steroid
anti-inflammatory drugs and systemic steroids, but re-
sults were disappointing [3–5, 9, 10]. Currently one
of the most effective treatments is biological therapy
[2, 4, 6–9, 11]. The medications of choice are the
TNF-α inhibitor etanercept and the IL-1 antagonist
anakinra. Based on Caorsi et al., treatment is ineffective in
43 % of cases with etanercept and in only 18 % of cases
with anakinra [4]. The recommended dose of anakinra
varies from 1 to 5 mg/kg/day. In our case, the minimum
dose of 1 mg/kg/day was effective at the beginning of
the disease. However, during the course of the disease
inflammation of gastrointestinal tract persisted and
the dose was increased. The new anti-IL-1 receptor
Fig. 1 Laboratory values. The figure demonstrates dynamics of the laboratory values (a – Hgb g/l, b – CRP mg/l, c – WBC *10e9/l) before
treatment and after treatment with systemic corticosteroids (on the 27th day of life) and anakinra (on the 60th day of life) was started
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antagonist canakinumab has showed promising results
in five patients [9]. Its main advantage is extended
exposure time and administration every 8 weeks.
Nevertheless biological therapy is effective for the sys-
temic inflammation it does not affect neurological
symptoms. As mentioned earlier, it is assumed that
brain development is mostly influenced by the disruption
in cholesterol synthesis [1, 10]. Exogenous cholesterol does
not pass the blood–brain barrier and therefore, neuronal
myelinisation and the stability of the brain cell membrane
is disturbed. Two cases of allogeneic bone marrow trans-
plantation when biological therapy was not efficient are de-
scribed in literature [7, 10]. Neven et al. presented a patient
who had mevalonate kinase function in lymphocytes up to
64 %, no episodes of fever, and no progression of neuro-
logical symptoms (ataxia level remained the same as before
transplantation) 15 months after transplantation [7].
Our case highlights the need for a very detailed clinical
and laboratory assessment of new-borns with any sugges-
tion of autoinflammatory disorders. Further investigation
such as metabolic screening should be considered in every
patient with persistent inflammatory markers with nega-
tive cultures. It is therefore important for patients to be
diagnosed as early as possible to provide better multidis-
ciplinary follow-up and therapy when needed. It is import-
ant for health care professionals to collect and publish
long term information about the course and treatment of
this rare disease for better understanding of it and more
qualified help for patients.
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